FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HCT type (check all that apply): 

 
 

gfedcb
Autologous

 
 

 
gfedcb

Allogeneic, unrelated

 
 

 
gfedcb

Allogeneic, related

 

Product type (check all that apply): 

 
 

gfedcb
Bone marrow

 
 

 
gfedcb

PBSC

 
 

 
gfedcb

Single cord blood unit

 
 

 
gfedcb

Multiple cord blood units

 
 

 
gfedcb

Other product

 
 
Specify:    

 
 

Is this the report of a second or subsequent transplant for the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 
 

1  Is this recipient a registered participant in the United States Immunodeficiency Network (USIDNET)?

    
 nmlkji

yes  
 nmlkji

no  

 
 
2  USIDNET ID:    

 
 
3  What was the date of diagnosis? __ __ __ __ - __ __- __ __  

 
 

4  Was genetic testing used to confirm the diagnosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

5  XLP1 / XLP (SH2D1A)

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 
 

6  XLP2 / XIAP (BIRC4)

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 
 

7  Other mutation

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not done  

 
 
8  Specify other mutation:    

 
 

9  Was documentation submitted to the CIBMTR?

    (e.g. pathology report)  

 nmlkji
yes  

 nmlkji
no  

 
 

10  Was X-linked inheritance demonstrated in the recipient’s maternal family members?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Subsequent Transplant 

  Disease Assessment at Diagnosis Questions: 1 - 23

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 8



 

Specify if the following disorders were present at diagnosis: 
 

11  Aplastic anemia

    
 nmlkji

yes  
 nmlkji

no  

 
 

12  Colitis

    
 nmlkji

yes  
 nmlkji

no  

 
 

13  Epstein-Barr Virus (EBV) infection with evidence of Hemophagocytic Lymphohistiocytosis (HLH)

    
 nmlkji

yes  
 nmlkji

no  

 
 

14  EBV infection without HLH

    
 nmlkji

yes  
 nmlkji

no  

 
 

15  Hypogammaglobulinemia

    
 nmlkji

yes  
 nmlkji

no  

 
 

16  Lymphoproliferative disorder

    
 nmlkji

yes  
 nmlkji

no  

 
 

17  Lymphoma

    
 nmlkji

yes  - Also complete Form 2018 - LYM 

 nmlkji
no  

 
 

18  Psoriasis

    
 nmlkji

yes  
 nmlkji

no  

 
 

19  Vasculitis

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the system(s) affected by vasculitis: 
 

20  Central nervous system

    
 nmlkji

yes  
 nmlkji

no  

 
 

21  Pulmonary system

    
 nmlkji

yes  
 nmlkji

no  

 
 

22  Other vasculitis involvement

    
 nmlkji

yes  
 nmlkji

no  

 
 
23  Specify other vasculitis involvement:    

 
 

24  Is there a history of EBV infection?

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Not evaluated  

 

Specify results used for diagnosis of EBV: 
 

25  In situ hybridization

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 
 

26  Polymerase chain reaction (PCR)

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 
 

27  Serology

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

  History of Epstein Barr Virus (EBV) Infection Questions: 24 - 32

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 8



 

Specify results: 
 

28  EBNA

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 

29  Early antigen

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 

30  Viral capsid IgG

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 

31  Viral capsid IgM

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 

32  Was documentation submitted to the CIBMTR?

    
 nmlkji

yes  
 nmlkji

no  

 
 

33  NK cell function

    
 nmlkji

Absent  (≤ 10% lower limit of normal) 

 nmlkji
Decreased   (11-50% lower limit of normal) 

 nmlkji
Normal  

 nmlkji
Unknown  

 
 

34  Invariant natural killer T-cells (iNKT)

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
35     m m³ 

 
 

36  Mucosal-associated invariant T-cells (MAIT)

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
37     m m³ 

 
 
38  Upper limit of normal of MAIT:    m m³ 

 
 
39  Lower limit of normal of MAIT:    m m³ 

 
 

40  Signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) expression

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 
 

41  XIAP protein expression

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 
 

42  Did the recipient receive supplemental intravenous immunoglobulins (IVIG)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

43  Was therapy ongoing within three months of immunoglobulin testing?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the quantitative immunoglobulins measured at diagnosis: 
 

44  IgG

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
45     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

46  IgM

    
 nmlkji

Known  
 nmlkji

Unknown  

  Assessment of Immunologic Function at Diagnosis Questions: 33 - 51

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 8



  
 
47     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

48  IgA

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
49     

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 

50  IgE

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
51     IU/mL 

 
 

52  Was HLH present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

53  Was the HLH triggered by an acute EBV infection?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

54  Was the HLH triggered by any other known condition(s)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

55  Bacterial infection

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  Fungal infection

    
 nmlkji

yes  
 nmlkji

no  

 
 

57  Malignancy

    
 nmlkji

yes  
 nmlkji

no  

 
 

58  Virus (not EBV)

    
 nmlkji

yes  
 nmlkji

no  

 
 
59  Specify virus   

 
 
60  Specify other virus:    

 
 

61  Other cause

    
 nmlkji

yes  
 nmlkji

no  

 
 
62  Specify other cause:    

 

Specify site(s) where HLH was present: 
 

63  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

 
 

65  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 

66  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

  Disease Assessment Between Diagnosis and the Start of the Preparative Regimen (Conditioning) Questions: 52 - 104

  Other Virus (1) Questions: 59 - 60 

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 8



 
 

67  Spleen

    
 nmlkji

yes  
 nmlkji

no  

 
 

68  Other site

    
 nmlkji

yes  
 nmlkji

no  

 
 
69  Specify other site:    

 
 

70  Was therapy given for HLH?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify therapy given for HLH: 
 

71  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
72  Date started: __ __ __ __ - __ __- __ __  

 
 

73  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
74  Date stopped: __ __ __ __ - __ __- __ __  

 
 

75  Alemtuzumab (Campath)

    
 nmlkji

yes  
 nmlkji

no  

 
 
76  Specify total dose given:    mg 

 
 

77  Antithymocyte globulin (ATG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  Corticosteroids

     (intrathecal)  (e.g. IT A-Hydrocort) 

 nmlkji
yes  

 nmlkji
no  

 
 

79  Corticosteroids

    (systemic) (e.g., Dexamethasone) 

 nmlkji
yes  

 nmlkji
no  

 
 

80  Cyclosporine (CSA, Neoral, Sandimmune)

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

82  Intrathecal methotrexate (IT MTX)

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  IVIG

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  Rituximab (Rituxan, MabThera)

    
 nmlkji

yes  
 nmlkji

no  

 
 
85  Specify number of doses given:    

 
 

86  Teniposide (VM26)

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  Other systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

  Line of Therapy (1) Questions: 71 - 88 

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 8



 
 
88  Specify other systemic therapy:    

 
 

89  Did colitis develop?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

90  Did vasculitis develop?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify vasculitis involvement: 
 

91  Central nervous system

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  Pulmonary system

    
 nmlkji

yes  
 nmlkji

no  

 
 

93  Other vasculitis involvement

    
 nmlkji

yes  
 nmlkji

no  

 
 
94  Specify other vasculitis involvement:    

 
 

95  Did the recipient develop lymphoma?

    
 nmlkji

yes  – Also complete Form 2018 - LYM 

 nmlkji
no  

 
 

96  Was the lymphoma associated with an EBV infection?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

97  Is the tumor EBV positive?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

98  Was documentation submitted to the CIBMTR?

    (e.g. pathology report)  

 nmlkji
yes  

 nmlkji
no  

 
 

99  Did the recipient develop hypogammaglobulinemia?

    
 nmlkji

yes  
 nmlkji

no  

 
 

100  Did the recipient develop aplastic anemia?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify therapy given for aplastic anemia: 
 

101  Growth factor

    
 nmlkji

yes  
 nmlkji

no  

 
 

102  Immunosuppression

    
 nmlkji

yes  
 nmlkji

no  

 
 

103  Other therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
104  Specify other therapy:    

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 8



 
 

105  Specify the status of HLH

    
 nmlkji

Active  

 nmlkji
Inactive  (quiescent) 

 nmlkji
Not applicable  

 
 

106  Was colitis active?

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 

107  Was the recipient receiving therapy for colitis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

108  Was the CNS vasculitis active?

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 

109  Was the recipient receiving therapy for CNS vasculitis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

110  Was pulmonary vasculitis active?

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 

111  Was the recipient receiving therapy for pulmonary vasculitis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

112  Was the other vasculitis active?

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 
 

113  Was the recipient receiving therapy for other vasculitis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the clinical and laboratory features assessed at last evaluation prior to the preparative regimen: 
 

114  Serum ferritin

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
115     µg/L 

 
 
116  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

117  Soluble interleukin-2 receptor (sIL-2R)

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
118     

 

 nmlkji
mg/dL  

 nmlkji
µmol/L  

 nmlkji
U/mL  

 
 
119  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

120  Triglycerides

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
121     

 

 nmlkji
mg/dL  

 nmlkji
mmol/L  

 
 
122  Date sample collected: __ __ __ __ - __ __- __ __  

 
 

123  Fibrinogen antigen assay (factor I; fibrinogen activity; functional fibrinogen; fibrinogen antigen)

    
 nmlkji

Known  
 nmlkji

Unknown  

  
 
124     

 

 nmlkji
g/dL  

 nmlkji
mg/dL  

 nmlkji
µmol/L  

 nmlkji
g/L  

 
 
125  Date sample collected: __ __ __ __ - __ __- __ __  

  Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen (Conditioning) Questions: 105 - 130

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 8



 
 

126  Bone marrow aspirate / biopsy evidence of hemophagocytosis

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Not done  

 

Specify the cerebrospinal fluid findings: 
 

127  Protein

    
 nmlkji

Normal  
 nmlkji

Elevated  
 nmlkji

Not done  

 
 

128  WBC count

    
 nmlkji

Normal  (≤ 5 cells/µL) 

 nmlkji
Elevated  (> 5 cells/µL) 

 nmlkji
Not done  

 
 

129  Was donor testing for XLP done prior to HCT?

    
 nmlkji

Yes  

 nmlkji
No  

 nmlkji
Not applicable   (related female and/or unrelated donor) 

 
 

130  Was there evidence of XLP?

    
 nmlkji

yes  
 nmlkji

no  

 
 
First Name:    

 
 
Last Name:    

 
 
E-mail address:    

 
 
Date: __ __ __ __ - __ __- __ __  

Form 2034 R3.0: X-Linked Lymphoproliferative Syndrome (XLP) Pre-HCT Data  
Center:  CRID: 

         CIBMTR Form 2034 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 8